Mallinckrodt price target raised to $95 from $85 at Jefferies Jefferies raised its price target for Mallinckrodt (MNK) shares to $95 and added the stock to its Franchise Picks list. The firm upped its estimates to reflect the Questcor (QCOR) acquisition and higher generic pricing. Jefferies thinks Mallinckrodt is well positioned to be either a buyer or a seller following the close of Questcor deal and it keeps a Buy rating on the stock.
Bellerophon expands license agreement with Mallinckrodt for INOpule development Bellerophon (BLPH) has expanded its license agreement with INO Therapeutics, a division of Mallinckrodt (MNK), allowing Bellerophon to develop INOpulse for the treatment of three additional cardiopulmonary diseases, including chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with sarcoidosis and pulmonary hypertension associated with pulmonary edema from high altitude sickness. Bellerophon's existing license with INO Therapeutics covers the development of INOpulse for pulmonary arterial hypertension, pulmonary hypertension associated with COPD and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Terms of the expanded license agreement include a 5% royalty on net sales for the three additional indications.